Amoy Diagnostics Co Ltd
SZSE:300685

Watchlist Manager
Amoy Diagnostics Co Ltd Logo
Amoy Diagnostics Co Ltd
SZSE:300685
Watchlist
Price: 23.51 CNY -1.84% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Amoy Diagnostics Co Ltd?
Write Note

Amoy Diagnostics Co Ltd
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Amoy Diagnostics Co Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Amoy Diagnostics Co Ltd
SZSE:300685
Long-Term Investments
ÂĄ22.4m
CAGR 3-Years
-31%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Long-Term Investments
ÂĄ635.2m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Long-Term Investments
ÂĄ2.3B
CAGR 3-Years
270%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Long-Term Investments
ÂĄ1.4B
CAGR 3-Years
89%
CAGR 5-Years
126%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Long-Term Investments
ÂĄ295.2m
CAGR 3-Years
6%
CAGR 5-Years
24%
CAGR 10-Years
39%
Imeik Technology Development Co Ltd
SZSE:300896
Long-Term Investments
ÂĄ1.9B
CAGR 3-Years
216%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Amoy Diagnostics Co Ltd
Glance View

Market Cap
9.4B CNY
Industry
Biotechnology

Amoy Diagnostics Co., Ltd., nestled in the bustling city of Xiamen, China, has carved out a niche in the world of molecular diagnostics. Founded in 2008, the company has quickly become a pioneer in precision medicine, focusing on the development and commercialization of technologies for the detection of genetic mutations. At the heart of its operation lies its proprietary ADx-ARMS technology, an innovative method allowing for the precise and sensitive detection of mutations in tumor tissues and blood, facilitating oncology diagnostics. This technology not only empowers oncologists with critical insights for tailored cancer treatments but underscores Amoy Diagnostics' commitment to transforming patient care through cutting-edge genetic testing. The commercial prowess of Amoy Diagnostics is, however, much more than its technological innovations. The company thrives on a robust business model that hinges on a symbiotic relationship with the pharmaceutical industry and healthcare providers. By offering diagnostic services and research kits, Amoy Diagnostics provides crucial support in the development of targeted therapies, enabling pharmaceutical companies to test and bring to market personalized medicine solutions. Their revenue stream is bolstered by strategic partnerships and licensing agreements, which allow them to expand their portfolio and market reach both domestically and internationally. This dynamic approach not only ensures a wide adoption of their diagnostic solutions but also firmly positions Amoy Diagnostics as a key player in the rapidly growing field of precision oncology.

Intrinsic Value
28.03 CNY
Undervaluation 16%
Intrinsic Value
Price

See Also

What is Amoy Diagnostics Co Ltd's Long-Term Investments?
Long-Term Investments
22.4m CNY

Based on the financial report for Sep 30, 2024, Amoy Diagnostics Co Ltd's Long-Term Investments amounts to 22.4m CNY.

What is Amoy Diagnostics Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
-22%

Over the last year, the Long-Term Investments growth was -56%. The average annual Long-Term Investments growth rates for Amoy Diagnostics Co Ltd have been -31% over the past three years , -22% over the past five years .

Back to Top